United States

Lonza Group AG (LZAGF.PK)

LZAGF.PK on OTC Markets Group

27 Oct 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Lonza raises guidance for core EBIT growth in 2016
Wednesday, 20 Jul 2016 01:04am EDT 

Lonza Group AG : Raising its guidance for core ebit growth and now expects a double-digit improvement in core ebit for full year of 2016 .Strong cash flow generation is expected to further reduce net debt significantly by end of fiscal year 2016.  Full Article

Lonza Group: Rodolfo Savitzky to succeed Toralf Haag as CFO
Tuesday, 10 May 2016 01:15am EDT 

Lonza Group AG : Rodolfo Savitzky to succeed Toralf Haag as Lonza Group CFO .Change will be effective as of October 1, 2016, when Rodolfo Savitzky will also succeed Toralf Haag as a member of Lonza Executive Committee.  Full Article

Lonza Group comments on first half of FY 2016 earnings outlook
Tuesday, 26 Apr 2016 01:00am EDT 

Lonza Group AG:Double-Digit core EBIT growth expected for first half of FY 2016.  Full Article

Lonza Group gives FY 2016 guidance and comments on mid-term FY 2018 outlook, proposes dividend
Wednesday, 27 Jan 2016 01:00am EST 

Lonza Group AG:‍In 2016 Lonza is expected to grow sales in line with 2018 guidance and targets a core EBIT growth of above 5 pct​.Sees ‍core EBITDA approaching 1 billion Swiss francs in 2018​ ‍.Sees ‍sales growth of low to mid-single digits on average per year until 2018​​.Proposing a stable dividend of 2.50 Swiss francs per share for FY 2015.  Full Article

Lonza Group comments on FY 2015 outlook
Thursday, 29 Oct 2015 02:00am EDT 

Lonza Group AG:Is confident that it will deliver sales growth in FY 2015.Lonza is planning for CORE EBIT growth of above 5 pct as a result of portfolio optimizations and further operational productivity improvements in FY 2015.  Full Article

Lonza Group AG reiterates full FY 2015 outlook
Tuesday, 21 Jul 2015 08:00pm EDT 

Lonza Group AG:Reiterates its full-FY 2015 outlook with sales growth in reported currency compared with last year’s sales and a CORE EBIT growth of at least 5 pct in constant exchange rates.Capital expenditure in 2015 is expected to remain below 300 million Swiss francs.  Full Article

Nikon and Lonza form collaboration for Cell and Gene Therapy Manufacturing in Japan
Thursday, 7 May 2015 02:00am EDT 

Lonza Group AG Nikon Corporation:Announces an exclusive collaboration in the field of cell and gene therapy manufacturing in Japan.Says Nikon will have access to Lonza's quality and operating systems, facility design and ongoing consulting services for the establishment of a wholly owned Nikon cell and gene therapy contract manufacturing business.The Tokyo/Yokohama area of Japan is currently under consideration for the site location of the Nikon's new facility.In addition, virally modified gene therapy has demonstrated promising clinical results in multiple disease indications, including cancer.Using viral vectors, immune and stem cells can be genetically modified and reintroduced to the patient as a targeted therapy.  Full Article

Lonza Group AG comments on FY 2015 and mid-term FY 2018 outlook
Tuesday, 28 Apr 2015 01:00am EDT 

Lonza Group AG:Sales and profit growth are expected for FY 2015 despite currency challenges.Says on track to deliver sales growth in 2015.Says planning for core EBIT growth of at least 5 pct as a result of portfolio optimizations and further operational productivity improvements.Core EBITDA will approach 1 billion Swiss francs in FY 2018.FY 2014 reported revenue 3.64 billion Swiss francs.FY 2015 revenue estimate 3.73 billion Swiss francs - Thomson Reuters I/B/E/S.  Full Article

arGEN-X announces a multi-product GS Xceed license agreement with Lonza Group
Wednesday, 18 Feb 2015 01:15am EST 

arGEN-X BV:Lonza Group AG and arGEN-X announce a multi-product GS Xceed license agreement for therapeutic antibodies.License secures long-term access for arGEN-X and its strategic partners to Lonza's GS Xceed system for creation and development of cell lines.Now has access to GS Xceed system for development and manufacture of both current and future therapeutic antibody products.  Full Article

TiGenix and Lonza sign agreement for the manufacture of stem cell-based treatment of complex perianal fistulas in Crohn’s Disease
Thursday, 12 Feb 2015 01:17am EST 

Lonza Group AG:Signs an agreement for the supply of TiGenix’s eASC product, Cx601.Under the agreement, Lonza will manufacture material for the Phase 3 trial of Cx601 in the US at Lonza’s cell therapy production facility in Walkersville, Maryland.  Full Article

BRIEF-Lonza Group expects to reach 2018 guidance year early

* Says strong momentum in q3 gives us confidence to specify that core ebit is on track to cross 15% growth line for full-year 2016